Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2021.13122

OL-23-01-13122

Articles

Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population

Ando

Yasuhisa

1 Kumamoto

Kensuke

1 Matsukawa

Hiroyuki

1 Ishikawa

Ryou

2 Suto

Hironobu

1 Oshima

Minoru

1 Kamada

Hideki

3 Morishita

Asahiro

3 Kobara

Hideki

3 Matsunaga

Toru

2 Haba

Reiji

2 Masaki

Tsutomu

3 Suzuki

Yasuyuki

1 Okano

Keiichi

1Department of Gastroenterological Surgery, Kagawa University, Miki, Kagawa 761-0793, Japan 2Department of Diagnostic Pathology, Kagawa University, Miki, Kagawa 761-0793, Japan 3Department of Gastroenterology and Neurology, Kagawa University, Miki, Kagawa 761-0793, Japan

Correspondence to: Dr Yasuhisa Ando, Department of Gastroenterological Surgery, Kagawa University, 1750-1 Ikenobe, Miki, Kita-gun, Kagawa 761-0793, Japan, E-mail: ando.yasuhisa.rf@kagawa-u.ac.jp

01 2022

04 11 2021

23 1

02072021 18102021

2021

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Recent studies have reported that immune checkpoint inhibitors are effective against various defective mismatch repair (dMMR)/microsatellite instability-high (MSI-H) cancers. A limited number of reports are available on the frequency of dMMR/MSI-H carcinoma in biliary tract cancer (BTC), describing its clinicopathological characteristics and prognosis. The latter carcinoma is also associated with Lynch syndrome (LS). The present study was performed to investigate the frequency of patients with dMMR/MSI-H in BTC and the clinical characteristics of BTC with dMMR/MSI-H in a single institution in Japan. A total of 116 patients with BTC who underwent curative surgical resection at Kagawa University Hospital between January 2008 and December 2017 were included. The protein expression levels of the mismatch repair (MMR) genes [mutL homolog 1 (MLH1), mismatch repair endonuclease PMS2 (PMS2), MutS homolog (MSH)2 and MSH6] were assessed by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded tissue specimens. Subsequently, MSI testing was performed on patients who exhibited loss of MMR protein expression. Loss of expression of one or more proteins was detected in five cases (4.3%). Loss of MLH1/PMS2 expression was observed in one case of intrahepatic cholangiocarcinoma, whereas loss of PMS2 expression was noted in one case of perihilar cholangiocarcinoma. Loss of MSH2/MSH6 and MSH6 expression was noted in two cases of distal cholangiocarcinoma and loss of PMS2 expression in one case of ampullary carcinoma. Out of the five patients, two demonstrated MSI-H. Microsatellite stability was observed in two cases and for one case, no data were available. Two MSI-H cases were patients with loss of expression of MLH1/PMS2 and MSH2/MSH6. None of the five patients exhibited a past medical history or family history of suspected LS. The frequency of dMMR in BTC was ~5%, which was similar to that reported by similar studies performed in other countries. In the present study, IHC appeared to be more useful than MSI testing for detecting MMR abnormalities with regards to the detection rate. Furthermore, there may only be a limited number of patients with BTCs who are likely to benefit from the therapeutic effects of treatment with immune checkpoint inhibitors.

biliary tract cancer defective mismatch repair microsatellite instability-high immunohistochemistry Lynch syndrome

Introduction

Malignant tumors derived from the biliary tract exhibit a variety of clinicopathological characteristics. These characteristics may be considered as epidemiological risk factors and may affect the diversity of the genetic architecture and the tissue microenvironment (1). Defective mismatch repair (dMMR) tumors are caused by loss of function of MMR proteins due to genetic (2) or epigenetic (3) events. This pathogenic variant in the germline of MMR genes [mutL homolog 1 (MLH1), MutS homolog (MSH)2, MSH6 and mismatch repair endonuclease PMS2 (PMS2)] is known to be the cause of Lynch syndrome (LS), a hereditary disease with a high incidence of colorectal and endometrial cancers. Numerous studies have reported on the expression of MMR proteins and on the incidence of microsatellite instability (MSI) status in biliary tract cancer (BTC), which is considered an LS-associated tumor (4–18). The approximate frequency of MSI-high (MSI-H) BTC is 5% for gallbladder carcinoma (GBCA), perihilar cholangiocarcinoma (pCCA) and distal CCA (dCCA), whereas it is estimated to be 10% for intrahepatic CCA (iCCA) and ampullary carcinoma (ampCA) (15).

In general, the treatment of BTC requires extended surgery, such as hepatectomy or pancreaticoduodenectomy, but the disease may be unresectable, depending on the patient's condition. Furthermore, BTC has poor prognosis due to the limited availability of effective chemotherapy options (19–22). Previous studies performed in recent years have reported that the immune checkpoint inhibitor anti-programmed death-1 (PD-1) antibody has a high response rate in patients with MSI-H. The latter is a genetic characteristic of certain solid tumors, is caused by dMMR and contributes to the overall survival of these patients (7,23,24). It has been previously reported that certain cases of MSI-H BTC may be successfully treated with pembrolizumab (25,26). Therefore, it is necessary to evaluate MMR protein expression and/or the MSI status in tumors in order to select patients who may be expected to benefit from treatment with anti-PD-1 antibodies.

In the case of colorectal (27) and endometrial (28) cancers, the concordance rate between immunohistochemistry (IHC) and MSI results is >90%, whereas such comparisons have not yet been made in patients with BTC. IHC is cost-effective and widely available in several facilities compared with MSI testing. Furthermore, IHC may be performed to determine the expression levels of the MMR genes that are likely to exhibit genetic/epigenetic changes (29,30).

The present study was performed to investigate the frequency of dMMR tumors and the clinical factors in dMMR cases using IHC. The aim was to determine the extent to which dMMR/MSI-H cases may be detected in BTCs resected at a single institution in Japan.

Patients and methods <sec> <title>Patients

The present study retrospectively enrolled patients who were diagnosed with BTC and underwent surgery between January 2008 and December 2017 at Kagawa University Hospital (Kagawa, Japan). A total of 116 patients were included in the present study. A total of 73 (62.9%) males and 43 (37.1%) females participated in the study. The demographic and clinicopathological data and the personal/family history of the patients were obtained from medical charts. Pathological tumor-node-metastasis staging was performed using the international system for BTC staging adopted by the American Joint Committee on Cancer and the Union for International Cancer Control, 8th edition (31). Table I presents the clinicopathological characteristics. The entire series consisted of iCCA (n=14, 12.1%), pCCA (n=17, 14.6%), dCCA (n=32, 27.6%), GBCA (n=30, 25.9%) and ampCA (n=23, 19.8%). The median age at diagnosis was 73 years (range, 38–93 years) and the majority of the included patients were aged ≥70 years (n=76; 65.5%).

IHC analysis for MMR protein detection

IHC was performed in order to assess the expression levels of four MMR proteins (MLH1, MSH2, MSH6 and PMS2) using a VENTANA MMR IHC Panel (Ventana Medical Systems, Inc.; Roche Diagnostics), according to the manufacturer's protocol. The samples were prepared from 4-µm formalin-fixed paraffin-embedded (FFPE) sections. The following primary antibodies were used for the detection of human (h) MMR proteins: Anti-hMLH1 antibody [cat. no. 518-114336; anti-MLH1 (M1) mouse monoclonal primary antibody], anti-hMSH2 antibody (cat. no. G219-1129; anti-MSH2 mouse monoclonal primary antibody), anti-hMSH6 antibody (cat. no. SP93; anti-MSH6 rabbit monoclonal primary antibody) and anti-hPMS2 antibody (cat. no. A16-4; anti-PMS2 mouse monoclonal primary antibody); all ready-to-use from Ventana Medical Systems, Inc.; Roche Diagnostics. The normal staining patterns for MLH1, MSH2, MSH6 and PMS2 were nuclear. The absence of nuclear staining in the tumor cells in the presence of nuclear staining of non-neoplastic cells, such as normal epithelial cells, lymphocytes and stromal cells, was considered to represent an abnormal pattern (29). The staining results were evaluated by consensus between two independent pathologists and surgeons, who were blinded to the clinical status of each patient.

DNA extraction

DNA was extracted from 4-µm FFPE sections of cancer tissues using the QIAamp DNA FFPE Tissue Kit (Qiagen GmbH).

MSI testing

MSI testing was performed in patients with dMMR and in 8 patients with a family history of LS-associated cancers. MSI testing was performed using the MSI analysis system, version 1.2 (Promega Corporation), which evaluates the MSI status of the following five mononucleotide microsatellite markers: BAT25, BAT26, NR21, MONO-27 and NR24 (32). Following amplification of the marker genes, the products were subjected to fragment analysis using the Applied Biosystems 3500 Genetic Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.) and GeneMapper software version 4.1 (Applied Biosystems; Thermo Fisher Scientific, Inc.). When two or more markers demonstrated altered numbers of repeats, the MSI status of the tumor was classified as MSI-H.

Statistical analysis

Descriptive statistics are reported as the median (range) for continuous variables and as frequency (%) for categorical variables. The overall survival was calculated as the time from surgery to the date of death (event) or the last follow-up date (censored) using the Kaplan-Meier method. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using JMP Pro version 14 (SAS Institute Inc.).

Results <sec> <title>IHC analysis

A total of 5 out of the 116 patients with BTC (4.3%) exhibited loss of expression of one or more proteins. Loss of MMR protein expression was observed for MLH1/PMS2 in one case of iCCA, for PMS2 in one case of pCCA, for MSH2/MSH6 and MSH6 in two cases of dCCA and for PMS2 in one case of ampCA (Fig. 1).

MSI assessment and clinicopathological and molecular characteristics of dMMR cases

MSI assessment was performed on five patients with dMMR as determined by IHC. A total of two patients (1.7%) exhibited MSI-H, with loss of MLH1/PMS2 (iCCA) loss of MSH2/MSH6 (dCCA) expression was noted in each of these two patients (Fig. 2). In one case with the loss of MSH6 (dCCA) expression, it was not possible to measure DNA amplification owing to suspected DNA degradation, whereas in two cases with the loss of PMS2 (pCCA) and PMS2 (ampCA) expression, MSI testing exhibited microsatellite stability (MSS). Table II indicates the clinicopathological characteristics of these patients with dMMR BTC. The patient age range was 55–93 years, with 3 (60%) males and 2 (40%) females, and none of the 5 patients had any history of cancer or family history of LS-associated disease. None of the patients survived; two succumbed to the original disease due to recurrence and the remaining three did not survive due to the presence of other conditions. Among 8 patients with a family history of LS-associated cancers, all cases exhibited both proficient MMR and MSS.

Discussion

The present study was performed at a single institution in Japan. The frequency of dMMR in BTC was 4.3% and that of MSI-H in BTC was 1.7%. In addition to the commonly performed evaluation of dMMR, which includes IHC analysis, MSI assessment was performed. In a case series of BTC, a small number of dMMR/MSI-H BTC was reported. Previous studies have reported that the prevalence of dMMR in BTCs is 0–9.4% (4,10,12,14,18). A large study, which used next-generation sequencing, reported a frequency of ~2% in BTCs (7). Previous studies that investigated the prevalence of MSI-H BTCs reported a frequency of 0–18% (5,6,8–14). Silva et al (15) reported that MSI-H accounted for ~5% of GBCA and extrahepatic CCA and for ~10% of iCCA and ampCA. Comparison of previous studies performed in Asia and Japan (6,8–11,16,33) with those from Western countries (4,5,12–14,34) indicated that the incidence of BTC with dMMR/MSI-H was almost the same in both Asian and Western countries (3.1 and 4.4%, respectively). Of note, the results of the present study were observed to be similar to those of the previous reports. However, while there were no MSI cases among patients with GBCA in the present cohort study, the frequency of dMMR/MSI-H cases in GBCA was ~5% in previous reports (15). In previous studies from Japan, Yoshida et al (35) determined a frequency of 0% (0/30), Yanagisawa et al (36) detected 6% (1/17), Nagahashi et al (37) reported 42% (8/19) and Akagi et al (33) 1.5% (3/200). The incidence of GBCA with dMMR/MSI-H was inconsistent even in Japan. The result of the present study showing that no MSI cases were observed in GBCA may be due to differences in population.

Several studies have reported concordant and discordant findings regarding the prevalence of dMMR and MSI-H in BTC. Previous studies on colorectal cancer have reported that IHC is also useful for the detection of dMMR with a sensitivity of 92% and for preventing MSI with a specificity of 99% (38–40). These results are different from those reported in the present study. Of the five cases with loss of MMR protein expression, two exhibited MSI-H. The prevalence of MSI-H BTC was lower than that of the dMMR tumors and discordant results were observed between IHC and PCR-based techniques. One case of MSH6 was reported in the current study, which was dMMR as assessed by IHC, but unmeasurable according to MSI testing. The resection specimen of this case was a paraffin-embedded section of an old specimen collected 9 years previously and therefore, it was hypothesized that the IHC staining result may have been compromised due to damage caused to the fixed tissue. The other two cases were deficient in PMS2 and the sensitivities of the MSI and IHC tests for detection of PMS2 mutations were 67 and 75%, respectively; thus, MSI testing was comparatively less sensitive (41,42). As mentioned earlier, inconsistencies have been reported in the results obtained between the two aforementioned methods (IHC and MSI testing). Therefore, these methods should be considered complementary. Specific differences in sensitivity have been reported depending on the mutated pathogenic gene. Therefore, it is considered that the therapeutic effect of anti-PD-1 antibodies may be expected if either dMMR or MSI-H is recognized.

In the present study, dMMR/MSI-H was observed in one case of MLH1/PMS2 and in one case of MSH2/MSH6. In general, the MLH1/PMS2 expression pattern suggested hypermethylation of MLH1 (43). It is considered that methylation is the cause of loss of MLH1 expression, which is observed in colorectal and uterine cancers, whereas loss of MSH2 expression may be due to somatic mutations in both alleles in addition to methylation. Tajima et al (44) reported that somatic mutations were also detected in both of these alleles in uterine carcinoma. In the present study, the five patients with loss of MMR protein expression did not survive and it was therefore impossible to perform an additional detailed genetic analysis. However, it was hypothesized that methylation and somatic alterations may have been associated with loss of MLH1 or MSH2 expression in the cases with dMMR/MSH-H, since these patients did not have any past history or family history of cancer. A study from Thailand (45) reported that CCA derived from liver fluke infection had a high incidence of MSI-H (9/13 cases, 69%). Although the pathogenesis of BTC in Japan is expected to be different from that in Thailand, the study will contribute to identify the mechanisms of alteration to MSI-H, leading to an increased understanding of the development of BTC.

BTC is also known as one of the important LS-associated tumors, as described in the revised Bethesda guidelines (46). Patients with colon and uterine cancers, which have a high frequency of dMMR/MSI-H, may be screened for the incidence of LS. In colon cancer, LS is diagnosed in ~3% of sporadic cases (47,48). Although eight patients had a family history of LS-associated cancers, they exhibited both proficient MMR and MSS. In the present study, none of the BTC patients with dMMR had a past medical history or family history of LS-associated cancers. Therefore, universal screening for all patients with newly diagnosed BTC may be an effective screening method, similar to that used for colorectal and uterine cancers.

A relatively large proportion of patients with BTC are diagnosed as unresectable (49) and even those who undergo curative resection have a high recurrence rate (50,51). A comparable treatment regimen to gemcitabine or cisplatin is yet to be established. The 5-year survival rate is 5–15% for all patients with BTC (19–21). In recent years, anti-PD-1 antibodies and immune checkpoint inhibitors have been reported to be effective in the treatment of various types of MSI-H solid tumors (23,52). It is expected for this therapeutic approach to improve the overall survival of patients with non-colorectal cancer who exhibit loss of MMR protein expression and/or MSI-H (53,54). Therefore, evaluation of MMR protein expression and/or MSI may be necessary to select patients with cancer who may benefit from treatment with anti-PD-1 antibodies. In the present study, the incidence of BTC with dMMR/MSI-H was ~5%, which is in agreement with that reported in previous studies (4,10,12,14,18). Based on these findings, it is suggested that screening should be routinely performed, since the prognosis of patients with BTC and dMMR/MSI-H was considerably poor.

There were certain limitations to the present study. First, it was performed at a single institution in the area of Shikoku, Japan. Therefore, the possibility of a regional selection bias among patients with BTC should be considered. Furthermore, all five patients with loss of MMR protein expression had already succumbed to the disease and it was not possible to perform any detailed genetic analysis on them. Finally, the difference between patients with pMMR and dMMR was not analyzed due to the low number of dMMR cases. In the future, additional data from other institutions must be collected in order to determine the exact prevalence of dMMR among patients with BTC.

The present study was a comprehensive study performed to examine the incidence of dMMR BTC in a hospital-based population in Japan. The data revealed a relatively low prevalence of dMMR cases. In the present study, IHC was indicated to be more useful than MSI testing for detecting MMR abnormalities with regards to the detection rate. Consequently, selected patients with BTC may benefit from the therapeutic effects of immune checkpoint inhibitors.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YA devised and designed the study. YA and KK analyzed and interpreted the patient data regarding biliary tract disease. HKa, AM, HKo and TsM contributed by providing medical preoperative diagnoses. RI, ToM and RH performed IHC and histopathological evaluations. KK, YS and KO were involved in drafting the manuscript and revising it critically for important intellectual content. YA, KK, HM, HS, MO, YS and KO designed the treatment plan and performed the surgeries. KK and KO confirm the authenticity of all the raw data. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Committee of Kagawa University (approval no. 2019-231). It conformed to the provisions of the Declaration of Helsinki. Written informed consent was obtained from the subjects in the form of an informative or disclosure document.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

dMMR

defective mismatch repair

MSI

microsatellite instability

Lynch syndrome

IHC

immunohistochemistry

UICC

Union for International Cancer Control

CCA

cholangiocarcinoma

iCCA

intrahepatic CCA

pCCA

perihilar CCA

dCCA

distal CCA

GBCA

gallbladder carcinoma

ampCA

ampullary carcinoma

PD-1

programmed death-1

References 1

Wardell

Fujita

Yamada

Simbolo

Fassan

Karlic

Polak

Kim

Hatanaka

Maejima

Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations

J Hepatol689599692018

10.1016/j.jhep.2018.01.009

29360550

Peltomäki

Update on Lynch syndrome genomics

Fam Cancer153853932016

10.1007/s10689-016-9882-8

26873718

Pal

Permuth-Wey

Sellers

A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer

Cancer1137337422008

10.1002/cncr.23601

18543306

Agaram

Shia

Tang

Klimstra

DNA mismatch repair deficiency in ampullary carcinoma: A morphologic and immunohistochemical study of 54 cases

Am J Clin Pathol1337727802010

10.1309/AJCPGDDE8PLLDRCC

20395525

Bonneville

Krook

Kautto

Miya

Wing

Chen

Reeser

Roychowdhury

Landscape of Microsatellite Instability Across 39 Cancer Types

JCO Precis Oncol20171152017

10.1200/PO.17.00073

29850653

Isa

Tomita

Nakachi

Miyazato

Shimoji

Kusano

Muto

Furukawa

Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma

Hepatogastroenterology496046082002

12063950

Durham

Smith

Wang

Bartlett

Aulakh

Kemberling

Wilt

Luber

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Science3574094132017

10.1126/science.aan6733

28596308

Liu

Momoi

Ishikawa

Fukumoto

Microsatellite instability in thorotrast-induced human intrahepatic cholangiocarcinoma

Int J Cancer1023663712002

10.1002/ijc.10726

12402306

Momoi

Itoh

Nozaki

Arima

Okabe

Satoh

Toda

Sakai

Nakagawara

Flemming

Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma

J Hepatol352352442001

10.1016/S0168-8278(01)00106-4

11580146

Park

Kim

Darwish

Kim

Lack of microsatellite instability in neoplasms of ampulla of Vater

Pathol Int536676702003

10.1046/j.1440-1827.2003.01534.x

14516316

Rashid

Ueki

Gao

Houlihan

Wallace

Wang

Shen

Deng

Hsing

K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: A population-based study in China

Clin Cancer Res8315631632002

12374683

Ruemmele

Dietmaier

Terracciano

Tornillo

Bataille

Kaiser

Wuensch

Heinmoeller

Homayounfar

Luettges

Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions

Am J Surg Pathol336917042009

10.1097/PAS.0b013e3181983ef7

19252434

Salem

Puccini

Grothey

Raghavan

Goldberg

Xiu

Korn

Weinberg

Hwang

Shields

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

Mol Cancer Res168058122018

10.1158/1541-7786.MCR-17-0735

29523759

Sessa

Furlan

Zampatti

Carnevali

Franzi

Capella

Prognostic factors for ampullary adenocarcinomas: Tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability

Virchows Arch4516496572007

10.1007/s00428-007-0444-1

17653761

Silva

Askan

Daniel

Lowery

Klimstra

Abou-Alfa

Shia

Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency

Chin Clin Oncol5622016

10.21037/cco.2016.10.04

27829276

Suto

Habano

Sugai

Uesugi

Kanno

Saito

Nakamura

Infrequent microsatellite instability in biliary tract cancer

J Surg Oncol761211262001

10.1002/1096-9098(200102)76:2<121::AID-JSO1022>3.0.CO;2-7

11223838

Ueno

Chung

Nagrial

Marabelle

Kelley

Mahoney

Pruitt

Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study

Ann Oncol29(Suppl 8)viii2102018

10.1093/annonc/mdy282.009

Winkelmann

Schneider

Hartmann

Schnitzbauer

Zeuzem

Peveling-Oberhag

Hansmann

Walter

Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital

Int J Mol Sci1914212018

10.3390/ijms19051421

29747443

Anderson

Kim

Adjuvant therapy for resected extrahepatic cholangiocarcinoma: A review of the literature and future directions

Cancer Treat Rev353223272009

10.1016/j.ctrv.2008.11.009

19147294

Brandi

Farioli

Astolfi

Biasco

Tavolari

Genetic heterogeneity in cholangiocarcinoma: A major challenge for targeted therapies

Oncotarget614744147532015

10.18632/oncotarget.4539

26142706

DeOliveira

Cunningham

Cameron

Kamangar

Winter

Lillemoe

Choti

Yeo

Schulick

Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution

Ann Surg2457557622007

10.1097/01.sla.0000251366.62632.d3

17457168

Valle

Wasan

Palmer

Cunningham

Anthoney

Maraveyas

Madhusudan

Iveson

Hughes

Pereira

ABC-02 Trial Investigators

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

N Engl J Med362127312812010

10.1056/NEJMoa0908721

20375404

Marabelle

Ascierto

Di Giacomo

De Jesus-Acosta

Delord

Geva

Gottfried

Penel

Hansen

Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study

J Clin Oncol381102020

10.1200/JCO.2020.38.4_suppl.1

31682550

Zayac

Almhanna

Hepatobiliary cancers and immunotherapy: Where are we now and where are we heading?

Transl Gastroenterol Hepatol582020

10.21037/tgh.2019.09.07

32190776

Czink

Kloor

Goeppert

Fröhling

Uhrig

Weber

Meinel

Sutter

Weiss

Schirmacher

Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer

Cold Spring Harb Mol Case Stud3a0019742017

10.1101/mcs.a001974

28619747

Naganuma

Sakuda

Murakami

Aihara

Watanuki

Suzuki

Shibasaki

Masuda

Uehara

Yasuoka

Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab

Intern Med59226122672020

10.2169/internalmedicine.4588-20

32536644

Lindor

Burgart

Leontovich

Goldberg

Cunningham

Sargent

Walsh-Vockley

Petersen

Walsh

Leggett

Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors

J Clin Oncol20104310482002

10.1200/JCO.2002.20.4.1043

11844828

Mills

Longacre

Lynch Syndrome: Female Genital Tract Cancer Diagnosis and Screening

Surg Pathol Clin92012142016

10.1016/j.path.2016.01.004

27241104

Chaves

Cruz

Lage

Claro

Cravo

Leitão

Soares

Immunohistochemical detection of mismatch repair gene proteins as a useful tool for the identification of colorectal carcinoma with the mutator phenotype

J Pathol1913553602000

10.1002/1096-9896(2000)9999:9999<::AID-PATH644>3.0.CO;2-T

10918209

Shia

Tang

Vakiani

Guillem

Stadler

Soslow

Katabi

Weiser

Paty

Temple

Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: A 2-antibody panel may be as predictive as a 4-antibody panel

Am J Surg Pathol33163916452009

10.1097/PAS.0b013e3181b15aa2

19701074

Brierley

Gospodarowicz

Wittekind

TNM Classification of Malignant Tumours, 8th Edition

Wiley-Blackwell

2016

Bando

Okamoto

Fukui

Yamanaka

Akagi

Yoshino

Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients

Cancer Sci109341134152018

10.1111/cas.13774

30142704

Akagi

Oki

Taniguchi

Nakatani

Aoki

Kuwata

Yoshino

The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors

Cancer Sci112110511132021

10.1111/cas.14798

33403729

Moy

Shahid

Ferrone

Borger

Zhu

Ting

Deshpande

Microsatellite instability in gallbladder carcinoma

Virchows Arch4663934022015

10.1007/s00428-015-1720-0

25680569

Yoshida

Sugai

Habano

Nakamura

Uesugi

Funato

Saito

Microsatellite instability in gallbladder carcinoma: Two independent genetic pathways of gallbladder carcinogenesis

J Gastroenterol357687742000

10.1007/s005350070036

11063221

Yanagisawa

Mikami

Yamashita

Okayasu

Microsatellite instability in chronic cholecystitis is indicative of an early stage in gallbladder carcinogenesis

Am J Clin Pathol1204134172003

10.1309/BYRNALP8GN63DHAJ

14502806

Nagahashi

Ajioka

Lang

Szentirmay

Kasler

Nakadaira

Yokoyama

Watanabe

Nishikura

Wakai

Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary

World J Gastroenterol1470752008

10.3748/wjg.14.70

18176964

Shia

Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry

J Mol Diagn102933002008

10.2353/jmoldx.2008.080031

18556767

Shia

Ellis

Klimstra

The utility of immunohistochemical detection of DNA mismatch repair gene proteins

Virchows Arch4454314412004

10.1007/s00428-004-1090-5

15455227

Shia

Klimstra

Nafa

Offit

Guillem

Markowitz

Gerald

Ellis

Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms

Am J Surg Pathol29961042005

10.1097/01.pas.0000146009.85309.3b

15613860

Hendriks

Jagmohan-Changur

van der Klift

Morreau

van Puijenbroek

Tops

van Os

Wagner

Ausems

Gomez

Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome)

Gastroenterology1303123222006

10.1053/j.gastro.2005.10.052

16472587

Palomaki

McClain

Melillo

Hampel

Thibodeau

EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

Genet Med1142652009

10.1097/GIM.0b013e31818fa2db

19125127

Kakar

Burgart

Thibodeau

Rabe

Petersen

Goldberg

Lindor

Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age

Cancer97142114272003

10.1002/cncr.11206

12627505

Tajima

Eguchi

Chika

Nagai

Dechamethakun

Kumamoto

Tachikawa

Akagi

Tamaru

Seki

Prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancer in a Japanese hospital-based population

Jpn J Clin Oncol487287352018

10.1093/jjco/hyy081

29889250

Loilome

Kadsanit

Muisook

Yongvanit

Namwat

Techasen

Puapairoj

Khuntikeo

Phonjit

Imbalanced adaptive responses associated with microsatellite instability in cholangiocarcinoma

Oncol Lett136396462017

10.3892/ol.2016.5477

28356940

Umar

Boland

Terdiman

Syngal

de la Chapelle

Rüschoff

Fishel

Lindor

Burgart

Hamelin

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

J Natl Cancer Inst962612682004

10.1093/jnci/djh034

14970275

Hampel

Frankel

Martin

Arnold

Khanduja

Kuebler

Clendenning

Sotamaa

Prior

Westman

Feasibility of screening for Lynch syndrome among patients with colorectal cancer

J Clin Oncol26578357882008

10.1200/JCO.2008.17.5950

18809606

Yurgelun

Kulke

Fuchs

Allen

Uno

Hornick

Ukaegbu

Brais

McNamara

Mayer

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer

J Clin Oncol35108610952017

10.1200/JCO.2016.71.0012

28135145

Valle

Advances in the treatment of metastatic or unresectable biliary tract cancer

Ann Oncol21(Suppl 7)vii345vii3482010

10.1093/annonc/mdq420

20943640

Wang

Lemieux

Kalpathy-Cramer

Ord

Walker

Fuller

Kim

Thomas

Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer

J Clin Oncol29462746322011

10.1200/JCO.2010.33.8020

22067404

Wang

Xia

Gong

Wang

Yan

Wan

Liu

Shi

Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy

J Clin Oncol31118811952013

10.1200/JCO.2012.41.5984

23358969

Homet Moreno

Ribas

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

Br J Cancer112142114272015

10.1038/bjc.2015.124

25856776

Dudley

Lin

Eshleman

Microsatellite Instability as a Biomarker for PD-1 Blockade

Clin Cancer Res228138202016

10.1158/1078-0432.CCR-15-1678

26880610

Uram

Wang

Kemberling

Eyring

Bartlett

Goldberg

Crocenzi

Fisher

Lee

PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers

J Clin Oncol34(Suppl 4)1951952016

10.1200/JCO.2016.34.15_suppl.103

Figure 1.

Expression pattern of MMR proteins in tissues from patients with biliary tract cancer and defective MMR. In case 1, loss of MLH1 and PMS2 was observed in the nuclei of cancer cells, while loss of MSH2 and MSH6 was observed in case 2. In case 3, loss of MSH6 was observed in the nuclear region of the cancer cells, while loss of PMS2 was observed in cases 4 and 5. The arrowheads indicate cancer cells (magnification, ×200). MMR, mismatch repair; MLH1, mutL homolog 1; PMS2, mismatch repair endonuclease PMS2; MSH, MutS homolog.

Figure 2.

Representative electropherograms of the cancer tissues exhibiting MSI-H. The presence of MSI for (A) case 1 and (B) case 2 is indicated. MSI-H is present when the maximal peak at each marker is situated outside the quasi-monomorphic variation range (gray zone). In cases 1 and 2, different-sized peaks were observed other than a distinctive peak from an allele (plus). Different-sized peaks were described as ‘positive’ and the results that did not yield peaks as ‘negative’. Five mononucleotide microsatellite markers: BAT25, BAT26, NR21, MONO-27 and NR24. MSI-H, MSI-high; MSI, microsatellite instability.

Table I.

Clinicopathological characteristics of the patient cohort.

Variable	Value
Sex
Male	73 (62.9)
Female	43 (37.1)
Age at diagnosis, years	73 (38–93)
<70	40 (34.5)
≥70	76 (65.5)
Localization
iCCA	14 (12.1)
pCCA	17 (14.6)
dCCA	32 (27.6)
GBCA	30 (25.9)
ampCA	23 (19.8)
History of LS-associated diseases
Yes	18 (15.5)
No	98 (84.5)
Family history of LS-associated diseases
Yes	8 (6.9)
No	108 (93.1)
Carcinoembryonic antigen, ng/ml^a	2.6 (0.8–35)
Normal	96 (84.2)
Abnormal	18 (15.8)
Carbohydrate antigen 19-9, U/ml^a	32.5 (2–63143)
Normal	61 (53.5)
Abnormal	53 (46.5)
Main differentiation
Papillary	20 (17.3)
Well	48 (41.4)
Moderate	31 (26.7)
Poor	10 (8.6)
Adenosquamous	7 (6)
Lymph node metastasis
0	73 (62.9)
1	43 (37.1)
Resection margin
0	104 (89.7)
1	12 (10.3)
UICC stage
1	31 (27)
2	48 (41.7)
3	30 (26.1)
4	6 (5.2)
Invasion into lymphatic vessels
0	38 (36.5)
1	66 (63.5)
Invasion into veins
0	42 (36.8)
1	72 (63.2)
0	47 (45.6)
1	56 (54.4)

Values are expressed as n (%) or the median (range).

The normal reference ranges of carcinoembryonic antigen and carbohydrate antigen 19-9 are 0-5 U/ml and 0-37 ng/ml, respectively. LS, Lynch syndrome; UICC, Union for International Cancer Control; CCA, cholangiocarcinoma; iCCA, intrahepatic CCA; pCCA, perihilar CCA; dCCA, distal CCA; GBCA, gallbladder carcinoma; ampCA, ampullary carcinoma.

Table II.

Clinicopathological and molecular characteristics of five cases of defective mismatch repair in biliary cancer.

Item	Case 1	Case 2	Case 3	Case 4	Case 5
Age, years	55	93	60	62	76
Sex	Male	Female	Female	Male	Male
Location	iCCA	dCCA	dCCA	pCCA	ampCA
Previous history of cancer	None	None	None	None	None
Family history	None	None	None	None	None
Immunohistochemistry	dMLH1/PMS2	dMSH2/MSH6	dMSH6	dPMS2	dPMS2
MSS status	MSI-H	MSI-H	Unmeasurable	MSS	MSS
BAT-25	+	+		−	−
BAT-26	+	+		−	−
NR-21	+	+		−	−
MONO-27	+	−		−	−
NR-24	+	+		−	−
Main differentiation	Well	Moderate	Poor	Well	Moderate
UICC stage	2	3A	1	3C	3A
Resection margin	0	0	1	0	0
Recurrence (location)	+ (Lymph node)	−	−	+ (Pulmonary)	−
Overall survival, months	17	6	48	37	34
Circumstance of death	DOD	DID	DID	DOD	DID

UICC, Union for International Cancer Control; CCA, cholangiocarcinoma; iCCA, intrahepatic CCA; pCCA, perihilar CCA; dCCA, distal CCA; ampCA, ampullary carcinoma; d, defective; MLH1, mutL homolog 1; PMS2, mismatch repair endonuclease PMS2; MSH, MutS homolog; MSI-H, microsatellite instability-high; MSS, microsatellite stability; DOD, died of disease; DID, died with intercurrent disease.